Main Uses and Therapeutic Intent

Doralin, containing the active substance quazepam, belongs to the benzodiazepine class of medications. It is primarily indicated for the management of insomnia characterized by difficulty falling asleep, frequent nocturnal awakenings, or early morning awakening.

The medication is designed to provide sedative and hypnotic effects by modulating neurotransmitter activity in the brain. Its pharmacological profile is intended to assist in the induction of sleep and the maintenance of sleep throughout the night.

Benefits and Clinical Effects

The clinical application of Doralin is focused on improving sleep parameters for patients experiencing transient or chronic sleep disturbances. Key therapeutic benefits include:

• Reduction in Sleep Latency: Decreasing the time required for a patient to transition from full wakefulness to sleep.
• Improvement in Sleep Maintenance: Reducing the number of times a patient wakes during the night, thereby promoting a more continuous sleep cycle.
• Increased Total Sleep Duration: Extending the overall time spent asleep to help the patient achieve a more restorative rest period.

By addressing these specific aspects of insomnia, the medication aims to help stabilize the sleep-wake cycle in individuals whose daily functioning may be affected by persistent sleep deprivation.

Eligibility: Official Regulatory Profile

Official regulatory documents define the strict population rules for Doralin (Otilonium Bromide), focusing on absolute prohibitions and restrictions.

Classification	Regulatory Status
Eligible Age Group	Adults (patients older than 18 years old).
Pediatric Use	Not recommended; safety and efficacy are not established below 18 years.
Pregnancy/Lactation	Not recommended / Preferable to avoid, unless absolutely necessary and under medical supervision.

Contraindications: Who Must Not Use

The medicine is contraindicated for patients with a known hypersensitivity or allergy to Otilonium Bromide or any of its inactive ingredients.

Some official labels list severe hepatic or renal impairment and obstructive bowel disorders as contraindications. Furthermore, the presence of lactose requires exclusion for patients with specific rare hereditary problems like galactose intolerance or total lactase deficiency.

Conditional Use Requiring Caution

Caution is specifically noted for use in patients with pre-existing conditions such as glaucoma, prostatic hypertrophy, or pyloric stenosis.

Interactions with other medicines and products

This section summarizes the official interaction information for Otilonium Bromide (Doralin) as documented in regulatory product labeling.

---

The regulatory profile for Otilonium Bromide is characterized by the absence of formally documented interaction studies in the official prescribing information. Consequently, regulatory sources list no specific interacting substances, detailed metabolic interaction warnings, or contraindicated drug combinations based on interaction mechanisms.

Official Interaction Statements

Category	Regulatory Statement
Documented Interaction Studies	None formally documented or performed according to regulatory labels.
Interacting Substances	None explicitly listed in regulatory interaction sections.
Timing Requirements	No mandatory time-separation rules are specified for co-administration with other medicines.
Impact on Other Oral Products	The medicine’s effect on gastrointestinal transit is assessed as not relevant for the systemic absorption of other concomitant oral medicinal products.

The regulatory documentation does not classify any interactions as severe or provide specific cautions for use with food, alcohol, or herbal products. The profile is limited to the constraints and findings stated in the regulatory label, defining the structure of the official interaction information.

Doralin's mechanism of action is defined by a multi-target, localized approach within the gastrointestinal tract, ensuring its activity is concentrated where excessive smooth muscle action occurs.

---

Direct Regulation of Smooth Muscle Contraction

The molecule's action begins by blocking L-type Calcium Channels (Ca^2+ channels), which are essential for initiating muscle fiber contraction. By restricting the influx of calcium ions, the mechanism causes a reduction in smooth muscle tension and contractility. This action directly inhibits excessive muscle movement (hypermotility) by limiting the core trigger for contraction.

---

Modulating Neural Signaling and Visceral Sensitivity

This mechanism involves a dual inhibitory action on the enteric nervous system (ENS). Doralin acts as an antagonist at two key receptor types: Muscarinic Receptors and Neurokinin-2 (NK2) Receptors. Antagonism at these sites reduces the excitatory signals that drive rapid movement and also restricts the afferent nerve signals that relay mechanical sensation. This coordinated neural modulation results in dampened enteric neurotransmission and a lowering of the threshold for afferent nerve signal transmission within the gut wall.

Doralin, which contains the active ingredient Otilonium Bromide in a 40 mg film-coated tablet, is intended strictly for oral administration. The standard approach to its use is defined by specific procedural conditions and dosage schedules.

The established adult dosing regimen specifies taking one 40 mg tablet per dose. This regimen is typically scheduled to occur two to three times daily, establishing the standard daily intake between 80 mg and 120 mg. To ensure proper drug availability, the tablet should be administered before meals, with instructions stating a preference for intake approximately 20 minutes prior to eating, along with a glass of water.

Procedural compliance requires that the film-coated tablet must be swallowed whole and must not be broken, crushed, or chewed. Regarding treatment duration, no fixed time limit is specified; the course of use is typically determined by the clinical presentation of the patient, supporting its role in a long-term management plan.

Usage rules for specific populations mandate that Doralin is not recommended for the pediatric population—that is, patients under 18 years of age. There are no specified dosage adjustments for individuals with hepatic or renal impairment. If a dose is missed, it is advised not to take a double dose to make up for the omission.

Research Evidence / Overview of Studies for Doralin (Otilonium Bromide)

---

Evidence for Use in Irritable Bowel Syndrome (IBS)

The primary research for Doralin was evaluated in adults with Irritable Bowel Syndrome (IBS), a condition characterized by fluctuating and episodic manifestations of abdominal discomfort and altered bowel habits. The core evidence consists of several key Randomized Controlled Trials (RCTs), where study participants were randomly assigned to receive the medicine or a placebo (an inactive substance). These RCTs are often summarized in comprehensive systematic reviews and meta-analyses, which combine data from multiple studies to contribute to the broader evidence landscape.

Research examined patient-reported outcomes describing perceived discomfort. Specifically, studies monitored changes in the severity and frequency of abdominal pain and abdominal discomfort. Researchers also explored symptom patterns related to abdominal bloating and distension (meteorism), along with monitoring physiological strain or stress as reflected in changes in bowel habits. Findings describe patterns observed in the studies, where patient-reported experiences related to overall symptom change were tracked over defined time intervals.

---

Long-Term Studies and Follow-up Research

The duration of the main clinical trials for Doralin primarily covered intermediate-term treatment periods, typically ranging from 4 weeks up to 15 weeks (approximately three to four months). These studies were designed to research exploring short-term symptom changes and to observe responses over defined time intervals. Follow-up periods, usually up to 10 weeks, examined the time taken for symptoms to return or worsen (relapse) after treatment cessation. The change in symptoms was observed to diminish upon cessation, contributing to understanding the natural course of symptoms in this condition.

---

What is Still Uncertain About Doralin Research

Follow-up durations were limited in the pivotal trials, meaning long-term effects are not fully established. There is limited high-quality information for long-term outcomes and the research strategy for managing the return of symptoms. One factor considered when interpreting findings is the inherent variability in patient response observed in IBS trials, meaning measured changes were associated with both the medicine and the placebo in some studies. Furthermore, data for certain groups remain insufficient, and certainty remains low for populations outside the primary adult study groups, such as children or older adults.

Key Studies & References

1. Submission for the classification of Otilonium bromide - 40 mg (Medsafe Regulatory Document referencing global usage and safety profile)

Common questions about Doralin (FAQ)

---

Q: Is it safe to drink alcohol while taking Doralin?

A: Official regulatory documents do not list any specific drug-alcohol interactions for Doralin. However, due to its classification as an anticholinergic medicine, and the possibility of uncommon side effects like dizziness, there is a theoretical potential for increased effects. Official information often suggests discussing alcohol consumption with a healthcare provider.

---

Q: What are the necessary steps for safely disposing of unused Doralin?

A: To prevent environmental contamination, Doralin must not be thrown away with household waste or disposed of via wastewater. Official instructions state that to discard expired or unused tablets correctly, information should be sought from a pharmacist. Disposal must comply with local pharmaceutical waste regulations.

---

Q: How should Doralin tablets be stored?

A: Doralin tablets are labelled with a storage temperature that must not exceed 30 C. Regulatory labeling specifies that the medicine is to be kept in the original blister and outer carton and protected from direct sunlight. As with all medicines, it is to be kept out of the sight and reach of children.

---

Q: Does Doralin interact with or affect other oral medications?

A: Regulatory documents state that no specific drug interactions have been formally documented for Doralin (Otilonium Bromide). Furthermore, official information indicates that the medicine's effect on the movement within the gut is considered not relevant to the systemic absorption of other oral medicines taken at the same time.

---

Q: What should I do if I take too much Doralin (overdose)?

A: Official guidelines state that in the event of a suspected overdose, a healthcare professional or emergency services should be contacted. Clinical safety studies have not reported fatal cases resulting from very high oral doses of the medicine.

---

Q: Where can I find the expiry date on the Doralin packaging?

A: The expiry date is clearly printed on the original packaging, typically on the outer carton and the blister pack containing the tablets. The medicine must not be used after this date has passed.

---

Q: Does Doralin cause drowsiness or affect my ability to drive?

A: Official labeling states that Doralin has a negligible or no influence on a person's ability to drive or use machines. However, uncommon side effects include headache and vertigo (dizziness). If symptoms like headache or dizziness are experienced, caution with activities requiring focus is typically warranted.

---

Q: Can Doralin be taken with herbal supplements or vitamins?

A: Regulatory product information does not list specific cautions for taking Doralin with food or herbal products. Due to the absence of documented interaction studies, co-administration of supplements and vitamins is typically an item for discussion with a healthcare provider.

Doralin (Otilonium Bromide) must be stored and disposed of according to the specific instructions provided in the official regulatory labeling.

Storage Requirements

Classification	Requirement
Storage Temperature	Do not store above 30 C.
Environmental Protection	Protect the medicine from direct sunlight.
Packaging Rule	Must be kept in the original blister and outer carton until use.
Child Safety	Keep this medicine out of the sight and reach of children.

Expiration and Disposal

The medicine must not be used after the expiry date printed on the packaging.

For disposal, the regulatory instructions prohibit throwing away any unused or expired tablets via wastewater or household waste to prevent environmental contamination. Users are instructed to ask a pharmacist for the correct method to discard the medicine, consistent with local pharmaceutical waste regulations.